JHU37160

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Boon, Paul: 1 article (01/2022)
2.	Carrette, Evelien: 1 article (01/2022)
3.	Delbeke, Jean: 1 article (01/2022)
4.	Desloovere, Jana: 1 article (01/2022)
5.	Goossens, Marie-Gabrielle: 1 article (01/2022)
6.	Larsen, Lars Emil: 1 article (01/2022)
7.	Raedt, Robrecht: 1 article (01/2022)
8.	Vonck, Kristl: 1 article (01/2022)
9.	Wadman, Wytse: 1 article (01/2022)

1.	Temporal Lobe Epilepsy 01/01/2022 - "To overcome the limitations of the commonly used DREADD agonist clozapine, we investigated the efficacy of the novel DREADD ligand JHU37160 in chemogenetic seizure suppression in the intrahippocampal kainic acid (IHKA) mouse model for temporal lobe epilepsy (TLE). "
2.	Seizures (Absence Seizure) 01/01/2022 - "Moreover, both compounds reduced the length of seizures that did occur after treatment up to 28 h and 18 h after clozapine and JHU37160, respectively. " 01/01/2022 - "Clozapine treatment suppressed seizures up to 34 h after treatment, and JHU37160 effects lasted for 26 h after injection. " 01/01/2022 - "These results show that the chemogenetic therapeutic strategy with either clozapine or JHU37160 effectively suppresses spontaneous seizures in the IHKA mouse model, confirming JHU37160 as an effective DREADD ligand. " 01/01/2022 - "Subsequently, animals were treated with LEV (800 mg/kg), clozapine (0.1 mg/kg), and DREADD ligand JHU37160 (0.1 mg/kg) and the effect on spontaneous seizures was investigated. "

1.	Aftercare (After-Treatment)